Trials / No Longer Available
No Longer AvailableNCT03564964
Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease
An Intermediate-Size, Expanded Access to SUVN-502 for the Treatment of Subjects With Alzheimer's Disease Who Have Completed the CTP2S1502HT6 Study
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Suven Life Sciences Limited · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- —
Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to SUVN-502 for the treatment of Alzheimer's Disease. Investigator as well as the subject/caregiver must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the patient's medical history and program eligibility criteria. Subjects will not be evaluated for efficacy and safety during the expanded access.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SUVN-502 | Tablet |
Timeline
- First posted
- 2018-06-21
- Last updated
- 2020-09-29
Source: ClinicalTrials.gov record NCT03564964. Inclusion in this directory is not an endorsement.